Ono Pharmaceutical Co., Ltd.
Native name
Company typePublic (K.K)
TYO: 4528
Founded1717; 307 years ago (1717) as Fushimiya Ichibei apothecary
FounderIchibei Ono I
Chuo-ku, Osaka, 541-8564
Area served
Key people
Gyo Sagara
(President and CEO)
RevenueIncrease JPY 261.8 billion (FY 2017) (US$ 2.4 billion) (FY 2017)
Decrease JPY 50.2 billion (FY 2017) (US$ 474 million) (FY 2017)
Number of employees
3,576 (consolidated, as of September 30, 2018)
WebsiteOfficial website
Footnotes / references
Ono Pharmaceutical's headquarters in Chūō-ku, Osaka, Japan

Ono Pharmaceutical Co., Ltd. (小野薬品工業株式会社, Ono Yakuhin Kōgyō Kabushiki-gaisha) is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka.,[4] and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.[5]

Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono (Japanese: 小野市兵衛) started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. (Japanese: 小野薬品工業株式会社) in 1948.[6]

Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.[7]

Nivolumab, the cancer drug based on the research of Prof.Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.[8]

See also


  1. ^ "Company Profile". Ono Pharmaceutical. Retrieved January 30, 2019.
  2. ^ "Company Profile". Nikkei Asian Review. Nikkei Inc. Retrieved January 30, 2019.
  3. ^ "About the company". Financial Times. Retrieved January 30, 2019.
  4. ^ Ono Pharmaceutical - Manufacturing
  5. ^ Ono Pharmaceutical - Research & Development
  6. ^ P. Reed Maurer (January 25, 2013). They Do Well Who Do Good: Insights into Japan's Pharmaceutical Industry. p. 132. ISBN 978-1-4669-5347-5.
  7. ^ "Company Overview of Ono Pharmaceutical Co., Ltd". bloomberg.com. Retrieved October 4, 2018.
  8. ^ "Spotlight on New Cancer Immunotherapy: Ono Pharmaceutical's Opdivo". Nippon.com. February 9, 2016. Retrieved October 4, 2018.